Product
Tebentafusp
Aliases
Tebentafusp (IMCgp100)
5 clinical trials
3 indications
Indication
MelanomaIndication
Uveal melanomaIndication
UvealClinical trial
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced MelanomaStatus: Completed, Estimated PCD: 2023-06-19
Clinical trial
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*0201 Positive Patients With High-risk Non-metastatic Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)Status: Not yet recruiting, Estimated PCD: 2032-11-01
Clinical trial
A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma With Molecular Relapsed DiseaseStatus: Recruiting, Estimated PCD: 2025-06-30